md-medicaldata

Authors

 

Dragan Turanjanin<sup>1,2

1</sup>Institut za zdravstvenu zaštitu dece i omladine Vojvodine
²Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad

 

UDK: 616.36-008.9-07
616-008.9-07

The paper was received / Rad primljen: 13.01.2024

Accepted / Rad prihvaćen: 21.02.2024

 

Correspondence to:

Dragan Turanjanin
Tome Maretića 55, Petrovaradin
tel: 065 3503609
e-mail: dturanjanin@icloud.com

 

 

Sažetak

 

 

Uvod. Nealkoholnu masnu bolest jetre (NMBJ) možemo definisati kao spektar  morfofunkcionalnih promena jetre, koje obavezno podrazumevaju nakupljanje triglicerida u hepatocitima, a zapaljenske promene kao i fibroza jetrenog parenhima ne moraju biti prisutni. Laboratorijska dijagnostika se bazira na određivanju jetrenih enzima, poput alanin aminotransferaze (ALT), aspartat aminotransferaze (AST), γ-glutamil transpeptidaze (γGT). Nealkoholna masna bolest jetre je često udružena sa insulinskom rezistencijom, dijabetes melitusom tip 2, dislipidemijom, hipertenzijom, kardiovaskularnim bolestima, gojaznošću i prisystvom metaboličkog sindroma. Cilj. Cilj rada je da ispita postojanje razlika antropometrijskih i laboratorijskih nalaza kod pacijenata sa nealkoholnom masnom bolesti jetre u odnosu na ispitanike bez nealkoholne masne promene jetre. Materijal i metode. Istraživanje je obuhvatalo 50 ispitanika. 20 ispitanika spadalo je u grupu pacijenata sa metaboličkim sindromom i razvijenom nealkoholnom masnom bolesti jetre, dok je 30 ispitanika (kontrola) imalo samo metabolički sindrom. Kod ispitanika su izvršena antropometrijska merenja i uzorkovana je venska krv za odgovarajuće analize. Rezultati. Postoji statistički značajna razlika u telesnoj težini (p = 0.00), indeksu telesne mase (p = 0.04), obimu struka (p = 0.00), odnosu obima struka prema obimu kuka (p = 0.01), vrednostima ALT (p = 0.01), AST (p = 0.01) i γGT (p = 0.04) između ispitanika sa NMBJ i osoba bez NMBJ. Zaključak. Odgovarajući antropometrijski i laboratorijski nalazi pokazuju statistički značajnu povezanost sa hepatosteatozom.

 

Ključne reči:

Nealkoholna masna bolest jetre; Hepatogram; Lipidni status; Antropometrija.

 

 

 

Abstract

 

Introduction. Non-alcoholic fatty liver disease (NAFLD) can be defined as a spectrum of morpho-functional changes in the liver that necessarily entails the accumulation of triglycerides in hepatocytes. Still, inflammatory changes and fibrosis of the liver parenchyma are not obligatory. Laboratory diagnostics are based on the determination of liver enzymes, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γGT). NAFLD is often associated with insulin resistance, type 2 diabetes mellitus, dyslipidemia, hypertension, cardiovascular disease, obesity and metabolic syndrome. The aim. The aim of this study is to investigate the differences between anthropometric and laboratory findings in patients with non-alcoholic fatty liver disease compared to subjects without non-alcoholic fatty liver disease. Material and methods. This study included 50 patients. Twenty patients were in the group of patients with NAFLD and metabolic syndrome, while 30 subjects (control group) had only metabolic syndrome. Anthropometric measures and venous blood samples were taken from the participants for appropriate analysis. Results. There was a statistically significant difference in body weight  (p=0.00), body mass index (p=0.04), waist circumference (p=0.00), waist circumference to hip circumference ratio (p=0.01), values of ALT (p=0.01), AST (p=0.01) and γGT (p=0.04) between patients with NAFLD and patients without NAFLD. Conclusion. Appropriate anthropometric and laboratory findings show a statistically significant association with hepatosteatosis.

 

Key words:

Non-alcoholic fatty liver disease; Hepatogram; Lipid status; Anthropometry.

 

 

 

 

References:

1. Clark JM, Brancati FL, Diehl AM. Non-alcoholic Fatty Liver Disease. Gastroenterology. 2002;122(6):1649-57.
2. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17:186-190.
3. Donnely KL, Smith CI, Schwarzenberg SJ, Jessurn J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-51.
4. Ballentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hrpatic steatosis in northern Italy. Ann Intern Med. 2000;132(2):112-7.
5. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metlab Disord. 1998;22(3):222-6.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106-10.
7. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85(10):1349-55.
8. Lam DW, LeRoith D. Metabolic Syndrome. In: De Groot LJ, Chrousos D, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.
9. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity. Gastroenterology. 1999;116(6):1413-19.
10. Ayonride OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, Klerk N, et al. Gender-Specific Difference in Adipose Distribution and Adipocytokines Influence Adolescent Non-alcoholic Fatty Liver Disease. Hepatology. 2011;53(3):800-9.
11. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of Non-alcoholic Fatty Liver Disease with Insulin Resistance. Am J Med. 1999;107(5):450-5.
12. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Non-alcoholic Fatty Liver Disease: a Feature of the Metabolic Syndrome. Diabetes. 2001;50(8):1844-50.
13. Vernon G, Baranova A, Younossi ZM. Systematic review: thr epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85.
14. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of Gender, Race, and Ethnicity on Suspected Fatty Liver in Obese Adolescents. Pediatrics. 2005;115(5):561-5.
15. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94(10):3010-4.
16. Ali AT, Paiker JE, Crowher CJ. The Relationship Between Anthropometry and Serum Concentrations of Alkaline Phosphatase Isoenzymes, Liver Enzymes, Albumin, and Bilirubin. Am J Clin Pathol. 2006;126(3):437-42.
17. Fabbrini E, Sullivan S, Klein S. Obesity and Non-alcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications. Hepatology. 2010;51(2):679-89.
18. Mittendorfer B, Magkos F, Fabbrini E, Mohammed BS, Klein S. Relationship between body fat mass and free fatty acids kinetics in men and women. Obesity. 2009;17(10);1872-7.
19. Arvind A, Osganian SA, Cohen DE, Corey K. Lipid and Lipoprotein Metabolism in Liver Disease. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, , et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.
20. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physol. 2008;294(5):1281-7.
21. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women eith non-alcoholic fatty liver disease. Gastroenterology 2008;134(2):424-31.
22. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(3):14-23.
23. Nagle CA, An J, Shiota M, Torres TP, Cline GW, Liu ZX, et al. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J Biol Chem. 2007;282(20):14807-15.
24. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118(9):2992-3002.
25. Dujmović F, Stošić Z, Đerić M. Praktikum iz patološke fiziologije. Medicinski fakultet Novi Sad, Novi Sad 2017.
26. Vitturi N, Soattin M, De Stefano F, Vianello D, Zambon A, Plebani M, et al. Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic faffy liver disease. Eat Weight Disord. 2015;20(2):241-7.
27. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62(3):392-9.
28. Lee JW, Cho YK, Ryan MC, Kim H, Lee SW, Chang E, et al. Serum Uric Acid as a Predictor for the Development of Non-alcoholic Fatty Liver Disease in Apparently Healthy Subjects: A 5-Year Retrospective Cohort Study. Gut Liver. 2010;4(3):378-83.
29. Xu C, Yu C, Xu L, Miao M, Li Y. High Serum Uric Acid Increases the Risk for Non-alcoholic Fatty Liver Disease: A Prospective Observational Study. PLoS One. 2010;5(7):e11578.
30. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab. 2010;48(2):175-80.
31. Dixon JB, Bhathal PS, O'Brien PE. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
    

PDF: 03-Turanjanin D. MD-Medical Data 2024;16(1) 023-029.pdf